These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 17182338

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment.
    Tappe D, Müller A, Stich A.
    Am J Trop Med Hyg; 2010 Jan; 82(1):1-3. PubMed ID: 20064985
    [No Abstract] [Full Text] [Related]

  • 4. Miltefosine for new world cutaneous leishmaniasis.
    Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H.
    Clin Infect Dis; 2004 May 01; 38(9):1266-72. PubMed ID: 15127339
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
    Ruiz-Villaverde R, Sánchez-Cano D, Villaverde-Gutierrez C.
    J Eur Acad Dermatol Venereol; 2007 May 01; 21(5):695-6. PubMed ID: 17447994
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
    Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J.
    Clin Infect Dis; 2001 Oct 01; 33(7):E57-61. PubMed ID: 11528586
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP, Marty P.
    Sante; 2001 Oct 01; 11(4):257-8. PubMed ID: 11861203
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
    Vélez I, López L, Sánchez X, Mestra L, Rojas C, Rodríguez E.
    Am J Trop Med Hyg; 2010 Aug 01; 83(2):351-6. PubMed ID: 20682881
    [Abstract] [Full Text] [Related]

  • 15. Miltefosine (Impavido) for leishmaniasis.
    Med Lett Drugs Ther; 2014 Sep 15; 56(1451):89-90. PubMed ID: 25211304
    [No Abstract] [Full Text] [Related]

  • 16. Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers.
    Eichner S, Thoma-Uszynski S, Herrgott I, Sebald H, Debus A, Tsianakas A, Ehrchen J, Harms G, Simon M, Sunderkötter C, Bogdan C.
    Eur J Dermatol; 2013 Apr 01; 23(2):218-23. PubMed ID: 23557633
    [Abstract] [Full Text] [Related]

  • 17. Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis.
    Joseph S, Whitman TJ, Buckner FS, Cogen AL.
    Am J Trop Med Hyg; 2021 May 10; 105(1):142-143. PubMed ID: 33970891
    [Abstract] [Full Text] [Related]

  • 18. Cutaneous leishmaniasis treatment.
    Minodier P, Parola P.
    Travel Med Infect Dis; 2007 May 10; 5(3):150-8. PubMed ID: 17448941
    [Abstract] [Full Text] [Related]

  • 19. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y.
    Am J Trop Med Hyg; 2006 Dec 10; 75(6):1074-7. PubMed ID: 17172368
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.